Agilent Announces Expanded Approval Of PD-L1 IHC 22C3 PharmDx In Esophageal Or GEJ Carcinoma

FDA approved Agilent's PD-L1 IHC 22C3 pharmDx (Code SK006) as a companion diagnostic to identify esophageal and gastroesophageal junction carcinoma patients who may be eligible for Merck's KEYTRUDA. The approval expands Agilent's oncology diagnostics offering and should modestly increase testing volumes and revenue exposure in cancer diagnostics while supporting KEYTRUDA uptake in the indicated indications.

Analysis

FDA approved Agilent's PD-L1 IHC 22C3 pharmDx (Code SK006) as a companion diagnostic to identify esophageal and gastroesophageal junction carcinoma patients who may be eligible for Merck's KEYTRUDA. The approval expands Agilent's oncology diagnostics offering and should modestly increase testing volumes and revenue exposure in cancer diagnostics while supporting KEYTRUDA uptake in the indicated indications.